Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies?
Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our November Discussion Group addressing ‘Bi-and Multi-Specific Antibodies - Formats, Applications, and Paths to the Clinic’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.
Workshop Speakers Include: Christian Klein, Department Head Cancer Immunotherapy Discovery 3, Roche Innovation Center Zurich | Julian Andreev, Research Fellow, Regeneron | Marlon Hinner, Principal Scientist & Group Leader, Roche Innovation Centre Munich | Danielle Mandikan, Scientist, Genentech
Antonin De Fougerolles, Chief Executive Officer, Evox Therapeutics
11 June 2019
Search by Keyword
Filter by Subject Area
Filter by Content Type
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.